

TDMS No. 99032 - 04
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol
CAS Number: 87-66-1

Date Report Requested: 08/17/2010
Time Report Requested: 13:34:47
First Dose M/F: 09/21/04 / 09/20/04
Lab: BAT

F1_M3

C Number: C99032
Lock Date: 03/04/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.2.0

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|------------------|---------|---------|----------|----------|
|------------------|---------|---------|----------|----------|

Disposition Summary

| | | | | |
|---|-----------|-----------|-----------|-----------|
| Animals Initially In Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Accidentally Killed | | | | 1 |
| Moribund Sacrifice | 8 | 10 | 10 | 12 |
| Natural Death | 5 | 4 | 6 | 6 |
| Survivors | | | | |
| Terminal Sacrifice | 37 | 36 | 34 | 31 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | |
|---|--------|---------|---------|--------|
| Esophagus | (50) | (50) | (50) | (50) |
| Inflammation | | | | 1 (2%) |
| Epithelium, Cyst | | | | 1 (2%) |
| Gallbladder | (49) | (49) | (50) | (46) |
| Cyst | 1 (2%) | | | |
| Infiltration Cellular, Mononuclear Cell | 4 (8%) | 8 (16%) | 4 (8%) | 3 (7%) |
| Epithelium, Hyperplasia | 1 (2%) | | 1 (2%) | |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Hyperplasia, Lymphoid | | | 1 (2%) | |
| Inflammation | | | 1 (2%) | |
| Epithelium, Hyperplasia | | | | 1 (2%) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) |
| Inflammation | | | 1 (2%) | |
| Epithelium, Hyperplasia | | | 2 (4%) | |
| Muscularis, Hypertrophy | | | 1 (2%) | |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Inflammation | | 1 (2%) | | |
| Epithelium, Hyperplasia | | 1 (2%) | | |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Inflammation | | 2 (4%) | 5 (10%) | |
| Epithelium, Hyperplasia | | 2 (4%) | 2 (4%) | |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|----------------------------------|----------|----------|----------|----------|
| Cyst | | | | 1 (2%) |
| Hyperplasia, Lymphoid | 9 (18%) | 5 (10%) | 5 (10%) | |
| Inflammation | 1 (2%) | 2 (4%) | 3 (6%) | |
| Inflammation, Granulomatous | 1 (2%) | | | |
| Epithelium, Hyperplasia | | 1 (2%) | | 1 (2%) |
| Liver | (50) | (50) | (50) | (50) |
| Angiectasis | | | 1 (2%) | |
| Atypia Cellular | | | | 1 (2%) |
| Basophilic Focus | 5 (10%) | 7 (14%) | 7 (14%) | 7 (14%) |
| Clear Cell Focus | 29 (58%) | 31 (62%) | 29 (58%) | 23 (46%) |
| Cytoplasmic Alteration | | 1 (2%) | 1 (2%) | |
| Degeneration, Fatty | | 1 (2%) | | |
| Eosinophilic Focus | 31 (62%) | 32 (64%) | 31 (62%) | 26 (52%) |
| Fibrosis | 1 (2%) | | | |
| Hematopoietic Cell Proliferation | | 4 (8%) | 4 (8%) | 14 (28%) |
| Hepatodiaphragmatic Nodule | 2 (4%) | | | |
| Infarct | | | 1 (2%) | |
| Inflammation | 31 (62%) | 25 (50%) | 29 (58%) | 24 (48%) |
| Metaplasia, Osseous | 1 (2%) | | | |
| Mixed Cell Focus | 5 (10%) | 5 (10%) | 6 (12%) | |
| Necrosis | 5 (10%) | 3 (6%) | 1 (2%) | 4 (8%) |
| Pigmentation | 2 (4%) | | 1 (2%) | 2 (4%) |
| Regeneration | 1 (2%) | | | |
| Tension Lipidosis | 2 (4%) | 3 (6%) | 4 (8%) | 2 (4%) |
| Thrombosis | | 1 (2%) | | |
| Vacuolization Cytoplasmic | 10 (20%) | 23 (46%) | 19 (38%) | 6 (12%) |
| Bile Duct, Cyst | | | | 3 (6%) |
| Bile Duct, Hyperplasia | 2 (4%) | 1 (2%) | 3 (6%) | 2 (4%) |
| Hepatocyte, Hypertrophy | 1 (2%) | | | |
| Kupffer Cell, Hyperplasia | 1 (2%) | | | 1 (2%) |
| Kupffer Cell, Pigmentation | 1 (2%) | | | |
| Oval Cell, Hyperplasia | 2 (4%) | | 1 (2%) | 1 (2%) |
| Mesentery | (8) | (6) | (8) | (10) |
| Inflammation | 3 (38%) | 1 (17%) | 2 (25%) | 2 (20%) |
| Fat, Necrosis | 4 (50%) | 2 (33%) | 3 (38%) | 3 (30%) |
| Oral Mucosa | (0) | (0) | (0) | (1) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Pancreas | (50) | (50) | (50) | (50) |
| Cytoplasmic Alteration, Focal | 1 (2%) | | | |
| Hemorrhage | | 1 (2%) | | |
| Infiltration Cellular, Mononuclear Cell | 9 (18%) | 14 (28%) | 15 (30%) | 9 (18%) |
| Inflammation | 2 (4%) | | | 1 (2%) |
| Pigmentation | | | | 1 (2%) |
| Vacuolization Cytoplasmic | 1 (2%) | | | |
| Acinus, Atrophy | 2 (4%) | 2 (4%) | 1 (2%) | |
| Duct, Cyst | 1 (2%) | | | 1 (2%) |
| Salivary Glands | (50) | (50) | (50) | (50) |
| Atrophy | | 1 (2%) | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | 40 (80%) | 40 (80%) | 41 (82%) | 40 (80%) |
| Inflammation | | | | 2 (4%) |
| Mineralization | 1 (2%) | 1 (2%) | 2 (4%) | |
| Duct, Hyperplasia | | | 1 (2%) | |
| Submandibular Gland, Vacuolization Cytoplasmic | 1 (2%) | | | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) |
| Hyperplasia | | 1 (2%) | | |
| Inflammation | 2 (4%) | 5 (10%) | 3 (6%) | 5 (10%) |
| Ulcer | 2 (4%) | | | 2 (4%) |
| Epithelium, Cyst | | | 1 (2%) | |
| Epithelium, Hyperkeratosis | 4 (8%) | 3 (6%) | 6 (12%) | 5 (10%) |
| Epithelium, Hyperplasia, Squamous | 3 (6%) | 5 (10%) | 6 (12%) | 7 (14%) |
| Stomach, Glandular | (50) | (50) | (50) | (50) |
| Cyst | 6 (12%) | 19 (38%) | 14 (28%) | 10 (20%) |
| Foreign Body | | 1 (2%) | | |
| Hyperplasia | 5 (10%) | 5 (10%) | 1 (2%) | 5 (10%) |
| Infiltration Cellular, Mononuclear Cell | | 4 (8%) | 2 (4%) | |
| Inflammation | | 1 (2%) | 5 (10%) | |
| Inflammation, Granulomatous | | | 1 (2%) | |
| Mineralization | 1 (2%) | 2 (4%) | | |
| Tooth | (36) | (30) | (24) | (22) |
| Dysplasia | 35 (97%) | 27 (90%) | 21 (88%) | 21 (95%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|--|----------|----------|----------|----------|
| CARDIOVASCULAR SYSTEM | | | | |
| Blood Vessel | (50) | (50) | (50) | (50) |
| Aorta, Infiltration Cellular, Mononuclear Cell | | 1 (2%) | | |
| Aorta, Mineralization | | 1 (2%) | | |
| Carotid Artery, Inflammation | 1 (2%) | | 3 (6%) | |
| Carotid Artery, Thrombosis | | | 1 (2%) | |
| Heart | (50) | (50) | (50) | (50) |
| Cardiomyopathy | 45 (90%) | 44 (88%) | 46 (92%) | 44 (88%) |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | 2 (4%) | 1 (2%) | 4 (8%) |
| Inflammation | 2 (4%) | 5 (10%) | 4 (8%) | 2 (4%) |
| Metaplasia, Osseous | | 1 (2%) | | |
| Mineralization | 1 (2%) | | 2 (4%) | 2 (4%) |
| Necrosis | 1 (2%) | | | |
| Thrombosis | 1 (2%) | | | |
| ENDOCRINE SYSTEM | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) |
| Angiectasis | | 2 (4%) | 2 (4%) | 1 (2%) |
| Fibrosis | 1 (2%) | | | |
| Hematopoietic Cell Proliferation | | | | 2 (4%) |
| Hyperplasia | 1 (2%) | | | |
| Hypertrophy | 15 (30%) | 18 (36%) | 13 (26%) | 8 (16%) |
| Inflammation | | 1 (2%) | | |
| Mineralization | | | 1 (2%) | |
| Vacuolization Cytoplasmic | | | 1 (2%) | |
| Subcapsular, Hyperplasia | 40 (80%) | 39 (78%) | 44 (88%) | 44 (88%) |
| Adrenal Medulla | (50) | (50) | (50) | (50) |
| Hyperplasia | | | 1 (2%) | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) |
| Hyperplasia | 43 (86%) | 43 (86%) | 42 (84%) | 40 (80%) |
| Parathyroid Gland | (41) | (44) | (42) | (47) |
| Hyperplasia | 1 (2%) | | | |
| Pituitary Gland | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pyrogallol

Time Report Requested: 13:34:47

Route: SKIN APPLICATION

CAS Number: 87-66-1

First Dose M/F: 09/21/04 / 09/20/04

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|------------------------------|---------|---------|----------|----------|
| Inflammation | 1 (2%) | | | |
| Pars Distalis, Hyperplasia | 2 (4%) | 1 (2%) | 2 (4%) | 1 (2%) |
| Pars Intermedia, Hyperplasia | | | 1 (2%) | |
| Thyroid Gland | (50) | (50) | (50) | (50) |
| Follicular Cell, Hyperplasia | | | 1 (2%) | |

GENERAL BODY SYSTEM

| | | | | |
|--------------|-----|----------|----------|----------|
| Peritoneum | (0) | (1) | (1) | (1) |
| Hyperplasia | | | 1 (100%) | |
| Inflammation | | 1 (100%) | | 1 (100%) |

GENITAL SYSTEM

| | | | | |
|---|----------|----------|----------|----------|
| Coagulating Gland | (0) | (2) | (1) | (0) |
| Epididymis | (50) | (50) | (50) | (50) |
| Fibrosis | 1 (2%) | | 2 (4%) | |
| Granuloma Sperm | | 2 (4%) | | 1 (2%) |
| Infiltration Cellular, Mononuclear Cell | 37 (74%) | 38 (76%) | 39 (78%) | 33 (66%) |
| Inflammation | 3 (6%) | 4 (8%) | 1 (2%) | 2 (4%) |
| Inflammation, Granulomatous | | 1 (2%) | | |
| Mineralization | | | 1 (2%) | |
| Pigmentation | | 1 (2%) | | |
| Artery, Inflammation | | 1 (2%) | | |
| Epithelium, Hyperplasia | | | | 1 (2%) |
| Penis | (1) | (0) | (0) | (0) |
| Inflammation | 1 (100%) | | | |
| Preputial Gland | (50) | (50) | (50) | (50) |
| Cyst | | | | 1 (2%) |
| Ectasia | 3 (6%) | 3 (6%) | 5 (10%) | 2 (4%) |
| Infiltration Cellular, Mononuclear Cell | 20 (40%) | 22 (44%) | 22 (44%) | 26 (52%) |
| Inflammation | 12 (24%) | 21 (42%) | 14 (28%) | 11 (22%) |
| Prostate | (50) | (50) | (50) | (50) |
| Fibrosis | | 1 (2%) | | |
| Hyperplasia | 12 (24%) | 21 (42%) | 15 (30%) | 19 (38%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pyrogallol

Time Report Requested: 13:34:47

Route: SKIN APPLICATION

CAS Number: 87-66-1

First Dose M/F: 09/21/04 / 09/20/04

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Hypertrophy | 1 (2%) | | | |
| Infiltration Cellular, Mononuclear Cell | 42 (84%) | 44 (88%) | 43 (86%) | 38 (76%) |
| Inflammation | 1 (2%) | 4 (8%) | 4 (8%) | 3 (6%) |
| Artery, Inflammation | | 1 (2%) | | |
| Seminal Vesicle | (50) | (50) | (50) | (50) |
| Infiltration Cellular, Mixed Cell | 1 (2%) | | | |
| Infiltration Cellular, Mononuclear Cell | 8 (16%) | 12 (24%) | 19 (38%) | 14 (28%) |
| Inflammation | | 5 (10%) | 1 (2%) | 1 (2%) |
| Bilateral, Dilatation | 1 (2%) | 2 (4%) | | |
| Testes | (50) | (50) | (50) | (50) |
| Atrophy | 1 (2%) | | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | | 2 (4%) | |
| Mineralization | | 1 (2%) | | 1 (2%) |

HEMATOPOIETIC SYSTEM

| | | | | |
|------------------------------------|---------|----------|----------|----------|
| Bone Marrow | (50) | (50) | (50) | (50) |
| Hyperplasia | 3 (6%) | 10 (20%) | 8 (16%) | 15 (30%) |
| Lymph Node | (10) | (12) | (9) | (16) |
| Axillary, Hyperplasia, Lymphoid | | | 1 (11%) | 3 (19%) |
| Bronchial, Hyperplasia, Lymphoid | 1 (10%) | 2 (17%) | 1 (11%) | |
| Inguinal, Hyperplasia, Lymphoid | 6 (60%) | 6 (50%) | 8 (89%) | 10 (63%) |
| Inguinal, Pigmentation | | 1 (8%) | | |
| Mediastinal, Hyperplasia, Lymphoid | | | | 3 (19%) |
| Mediastinal, Inflammation | | | | 1 (6%) |
| Renal, Necrosis | | | | 1 (6%) |
| Lymph Node, Mandibular | (50) | (50) | (50) | (50) |
| Hematopoietic Cell Proliferation | | | | 1 (2%) |
| Hyperplasia, Lymphoid | 9 (18%) | 16 (32%) | 12 (24%) | 11 (22%) |
| Inflammation | | | | 1 (2%) |
| Lymph Node, Mesenteric | (50) | (49) | (50) | (49) |
| Angiectasis | | | 1 (2%) | |
| Hyperplasia, Lymphoid | 5 (10%) | 7 (14%) | 10 (20%) | 3 (6%) |
| Inflammation | 1 (2%) | | 1 (2%) | 1 (2%) |
| Pigmentation | 1 (2%) | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|-----------|-----------|
| Spleen | (50) | (49) | (50) | (50) |
| Angiectasis | | | | 1 (2%) |
| Hematopoietic Cell Proliferation | 37 (74%) | 38 (78%) | 40 (80%) | 42 (84%) |
| Hyperplasia, Lymphoid | 5 (10%) | 2 (4%) | 3 (6%) | 5 (10%) |
| Inflammation | | | | 1 (2%) |
| Pigmentation | | | 1 (2%) | |
| Thymus | (48) | (50) | (46) | (48) |
| Hyperplasia, Lymphoid | 2 (4%) | 2 (4%) | 1 (2%) | 1 (2%) |
| INTEGUMENTARY SYSTEM | | | | |
| Mammary Gland | (0) | (0) | (0) | (1) |
| Hyperplasia | | | | 1 (100%) |
| Skin | (50) | (50) | (50) | (50) |
| Abscess | | 1 (2%) | | |
| Fibrosis | 1 (2%) | 1 (2%) | 3 (6%) | 10 (20%) |
| Hyperkeratosis | 1 (2%) | 1 (2%) | 3 (6%) | 10 (20%) |
| Hyperplasia | 1 (2%) | 1 (2%) | 3 (6%) | 10 (20%) |
| Inflammation | 1 (2%) | 1 (2%) | 3 (6%) | 10 (20%) |
| Metaplasia, Cartilagenous | | | | 1 (2%) |
| Ulcer | | 1 (2%) | 3 (6%) | 10 (20%) |
| Control, Inflammation | | | 1 (2%) | 1 (2%) |
| Hair Follicle, Site Of Application, Cyst | | | | 1 (2%) |
| Lip, Inflammation | | 1 (2%) | | |
| Sebaceous Gland, Hyperplasia | 1 (2%) | 1 (2%) | | 5 (10%) |
| Sebaceous Gland, Site Of Application, Hyperplasia | 1 (2%) | 6 (12%) | 4 (8%) | 24 (48%) |
| Site Of Application, Fibrosis | 3 (6%) | 6 (12%) | 28 (56%) | 47 (94%) |
| Site Of Application, Hyperkeratosis | 11 (22%) | 43 (86%) | 50 (100%) | 50 (100%) |
| Site Of Application, Hyperplasia | 8 (16%) | 24 (48%) | 47 (94%) | 50 (100%) |
| Site Of Application, Inflammation | 2 (4%) | 6 (12%) | 37 (74%) | 44 (88%) |
| Site Of Application, Pigmentation | | | 9 (18%) | 39 (78%) |
| Site Of Application, Ulcer | 1 (2%) | 1 (2%) | 2 (4%) | 23 (46%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|---------|----------|----------|----------|
| MUSCULOSKELETAL SYSTEM | | | | |
| Bone | (50) | (50) | (50) | (50) |
| Cranium, Hyperostosis | | | 1 (2%) | 1 (2%) |
| Cranium, Inflammation | 1 (2%) | | | 1 (2%) |
| Skeletal Muscle | (0) | (0) | (1) | (2) |
| Inflammation | | | 1 (100%) | |
| Mineralization | | | | 1 (50%) |
| NERVOUS SYSTEM | | | | |
| Brain | (50) | (50) | (50) | (50) |
| Developmental Malformation | 1 (2%) | | | |
| Infiltration Cellular, Mononuclear Cell | 4 (8%) | 2 (4%) | | 1 (2%) |
| Inflammation | 1 (2%) | | | 1 (2%) |
| Cerebellum, Gliosis | | | | 1 (2%) |
| Choroid Plexus, Mineralization | 1 (2%) | | | |
| RESPIRATORY SYSTEM | | | | |
| Lung | (50) | (50) | (50) | (50) |
| Infiltration Cellular, Histiocyte | 5 (10%) | 12 (24%) | 7 (14%) | 6 (12%) |
| Inflammation | 7 (14%) | 3 (6%) | 5 (10%) | 3 (6%) |
| Metaplasia, Osseous | | 1 (2%) | | 2 (4%) |
| Mineralization | | 1 (2%) | 1 (2%) | |
| Pigmentation | 1 (2%) | 3 (6%) | 2 (4%) | |
| Thrombosis | | | 1 (2%) | |
| Alveolar Epithelium, Hyperplasia | 7 (14%) | 3 (6%) | 3 (6%) | 5 (10%) |
| Bronchiole, Hyperplasia | | 1 (2%) | | 1 (2%) |
| Bronchiole, Mineralization | 1 (2%) | | | |
| Interstitialium, Fibrosis | | | 1 (2%) | |
| Mediastinum, Necrosis, Fatty | | | | 1 (2%) |
| Nose | (50) | (50) | (50) | (50) |
| Foreign Body | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|--------------------------------------|----------|----------|----------|----------|
| Inflammation | 20 (40%) | 15 (30%) | 16 (32%) | 15 (30%) |
| Necrosis | | | | 1 (2%) |
| Polyp, Inflammatory | 2 (4%) | 2 (4%) | 2 (4%) | 1 (2%) |
| Glands, Dilatation | 2 (4%) | | 1 (2%) | 2 (4%) |
| Glands, Fibrosis | 1 (2%) | | | |
| Glands, Metaplasia | 11 (22%) | 3 (6%) | 1 (2%) | 3 (6%) |
| Goblet Cell, Hyperplasia | | | | 2 (4%) |
| Olfactory Epithelium, Degeneration | 2 (4%) | | | 3 (6%) |
| Olfactory Epithelium, Hyperplasia | 1 (2%) | 1 (2%) | 1 (2%) | |
| Olfactory Epithelium, Metaplasia | 11 (22%) | 8 (16%) | 4 (8%) | 5 (10%) |
| Respiratory Epithelium, Degeneration | 2 (4%) | | 1 (2%) | |
| Respiratory Epithelium, Hyperplasia | 40 (80%) | 45 (90%) | 46 (92%) | 37 (74%) |
| Respiratory Epithelium, Metaplasia | 2 (4%) | 1 (2%) | | 1 (2%) |
| Vomeranasal Organ, Cyst | | | 1 (2%) | |

SPECIAL SENSES SYSTEM

| | | | | |
|---|----------|----------|----------|----------|
| Eye | (50) | (50) | (50) | (50) |
| Cataract | | | 1 (2%) | 1 (2%) |
| Developmental Malformation | | | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | | | 1 (2%) | |
| Inflammation | 4 (8%) | 2 (4%) | 3 (6%) | 1 (2%) |
| Cornea, Hyperplasia | 2 (4%) | 1 (2%) | | 1 (2%) |
| Harderian Gland | (50) | (50) | (50) | (50) |
| Cyst | 1 (2%) | | | |
| Hyperplasia | 3 (6%) | 1 (2%) | 1 (2%) | 3 (6%) |
| Infiltration Cellular, Mononuclear Cell | 35 (70%) | 41 (82%) | 41 (82%) | 36 (72%) |
| Inflammation | 1 (2%) | | | 1 (2%) |

URINARY SYSTEM

| | | | | |
|-------------------------------|------|---------|---------|--------|
| Kidney | (50) | (50) | (50) | (50) |
| Accumulation, Hyaline Droplet | | | | 1 (2%) |
| Cyst | | 5 (10%) | 9 (18%) | 4 (8%) |
| Dilatation | | 2 (4%) | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Hyperplasia, Oncocytic | | | | 1 (2%) |
| Infarct | | 1 (2%) | | |
| Infiltration Cellular, Mononuclear Cell | 2 (4%) | | 5 (10%) | 4 (8%) |
| Inflammation | 1 (2%) | 3 (6%) | 2 (4%) | 2 (4%) |
| Metaplasia, Osseous | 6 (12%) | 2 (4%) | | |
| Mineralization | 39 (78%) | 42 (84%) | 34 (68%) | 38 (76%) |
| Nephropathy | 44 (88%) | 46 (92%) | 47 (94%) | 45 (90%) |
| Pigmentation | 1 (2%) | | | 1 (2%) |
| Thrombosis | 1 (2%) | 1 (2%) | | |
| Papilla, Necrosis | | 1 (2%) | | |
| Renal Tubule, Hyperplasia | 3 (6%) | 2 (4%) | 1 (2%) | 1 (2%) |
| Urethra | (0) | (1) | (1) | (1) |
| Inflammation | | 1 (100%) | | 1 (100%) |
| Bulbourethral Gland, Inflammation | | 1 (100%) | 1 (100%) | |
| Bulbourethral Gland, Necrosis | | 1 (100%) | | |
| Transitional Epithelium, Hyperplasia | | 1 (100%) | | |
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Infiltration Cellular, Mononuclear Cell | 20 (40%) | 31 (62%) | 33 (66%) | 23 (46%) |
| Inflammation | | 1 (2%) | 2 (4%) | |

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|--------------------|---------|---------|----------|----------|
|--------------------|---------|---------|----------|----------|

Disposition Summary

| | | | | |
|----------------------------------|----|----|----|----|
| Animals Initially In Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Moribund Sacrifice | 9 | 15 | 7 | 29 |
| Natural Death | 8 | 5 | 7 | 4 |
| Survivors | | | | |
| Natural Death | | | | 1 |
| Terminal Sacrifice | 33 | 30 | 36 | 16 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | |
|---|--------|---------|---------|---------|
| Esophagus | (50) | (50) | (50) | (50) |
| Inflammation | | | 1 (2%) | |
| Epithelium, Hyperplasia | | | 1 (2%) | |
| Gallbladder | (50) | (49) | (49) | (50) |
| Cyst | 1 (2%) | | | 1 (2%) |
| Infiltration Cellular, Mononuclear Cell | 4 (8%) | 7 (14%) | 6 (12%) | 6 (12%) |
| Inflammation | 1 (2%) | | | |
| Epithelium, Hyperplasia | | 1 (2%) | | |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Inflammation | 1 (2%) | | | |
| Epithelium, Hyperplasia | | 1 (2%) | | |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Artery, Inflammation | | | | 1 (2%) |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) |
| Artery, Inflammation | | | | 1 (2%) |
| Epithelium, Hyperplasia | | | 1 (2%) | |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Inflammation | 1 (2%) | | | |
| Epithelium, Hyperplasia | | | 1 (2%) | |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Inflammation | 1 (2%) | 1 (2%) | | 1 (2%) |
| Epithelium, Hyperplasia | 1 (2%) | 1 (2%) | 3 (6%) | |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|-------------------|----------|----------------------------|----------|
| Hyperplasia, Lymphoid Inflammation Epithelium, Hyperplasia | 2 (4%) | 5 (10%) | 2 (4%) 2 (4%) 1 (2%) | 2 (4%) |
| Liver | (50) | (50) | (50) | (50) |
| Angiectasis | 2 (4%) | | 2 (4%) | |
| Atrophy | | | 1 (2%) | |
| Basophilic Focus | 8 (16%) | 2 (4%) | 3 (6%) | 2 (4%) |
| Clear Cell Focus | 10 (20%) | 1 (2%) | 3 (6%) | 1 (2%) |
| Eosinophilic Focus | 26 (52%) | 28 (56%) | 31 (62%) | 12 (24%) |
| Fibrosis | 1 (2%) | 1 (2%) | | |
| Hematopoietic Cell Proliferation | 9 (18%) | 8 (16%) | 9 (18%) | 30 (60%) |
| Hypertrophy, Diffuse Inflammation | 40 (80%) | 32 (64%) | 43 (86%) | 37 (74%) |
| Mixed Cell Focus | 6 (12%) | 7 (14%) | 4 (8%) | 1 (2%) |
| Necrosis | 8 (16%) | 5 (10%) | 2 (4%) | 6 (12%) |
| Pigmentation | | 1 (2%) | | |
| Tension Lipidosis | 7 (14%) | 6 (12%) | 7 (14%) | 10 (20%) |
| Vacuolization Cytoplasmic Centrilobular, Hepatocyte, Degeneration | 7 (14%) 1 (2%) | 5 (10%) | 6 (12%) | 1 (2%) |
| Mesentery | (20) | (22) | (14) | (19) |
| Inflammation | 2 (10%) | 2 (9%) | | 1 (5%) |
| Thrombosis | 1 (5%) | | | |
| Fat, Necrosis | 12 (60%) | 10 (45%) | 11 (79%) | 15 (79%) |
| Fat, Thrombosis | | 1 (5%) | | |
| Pancreas | (50) | (50) | (50) | (50) |
| Atrophy | | | | 1 (2%) |
| Infiltration Cellular, Mononuclear Cell | 31 (62%) | 25 (50%) | 24 (48%) | 21 (42%) |
| Inflammation | 3 (6%) | | | 4 (8%) |
| Acinus, Atrophy | 3 (6%) | 1 (2%) | 1 (2%) | 2 (4%) |
| Artery, Inflammation | | 1 (2%) | | |
| Duct, Cyst | 1 (2%) | | | |
| Salivary Glands | (50) | (50) | (50) | (50) |
| Atrophy | | | | 1 (2%) |
| Infiltration Cellular, Mononuclear Cell | 36 (72%) | 37 (74%) | 38 (76%) | 30 (60%) |
| Inflammation | | | 1 (2%) | 1 (2%) |
| Mineralization | | 1 (2%) | | 2 (4%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Stomach, Forestomach | (50) | (50) | (50) | (50) |
| Hyperplasia | | 1 (2%) | | |
| Infiltration Cellular, Mononuclear Cell | | | 1 (2%) | 2 (4%) |
| Infiltration Cellular, Diffuse | | | | 1 (2%) |
| Inflammation | | 5 (10%) | 2 (4%) | |
| Ulcer | | 3 (6%) | 1 (2%) | |
| Epithelium, Hyperkeratosis | 1 (2%) | 6 (12%) | 2 (4%) | 1 (2%) |
| Epithelium, Hyperplasia, Squamous | 2 (4%) | 9 (18%) | 3 (6%) | 1 (2%) |
| Stomach, Glandular | (50) | (50) | (50) | (50) |
| Cyst | 15 (30%) | 18 (36%) | 15 (30%) | 14 (28%) |
| Hyperplasia | 3 (6%) | 1 (2%) | 1 (2%) | 4 (8%) |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | 4 (8%) | 5 (10%) | 2 (4%) |
| Infiltration Cellular, Diffuse | | | | 1 (2%) |
| Inflammation | | 3 (6%) | 1 (2%) | 1 (2%) |
| Mineralization | | | 1 (2%) | 2 (4%) |
| Necrosis | | 1 (2%) | | |
| Ulcer | | 1 (2%) | 1 (2%) | |
| Tooth | (3) | (0) | (4) | (0) |
| Dysplasia | 3 (100%) | | 4 (100%) | |

CARDIOVASCULAR SYSTEM

| | | | | |
|---|----------|----------|----------|----------|
| Blood Vessel | (50) | (50) | (50) | (50) |
| Inflammation | 1 (2%) | | | |
| Carotid Artery, Mineralization | | 1 (2%) | | |
| Heart | (50) | (50) | (50) | (50) |
| Cardiomyopathy | 42 (84%) | 33 (66%) | 35 (70%) | 38 (76%) |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | 3 (6%) | 4 (8%) | 3 (6%) |
| Inflammation | 3 (6%) | 3 (6%) | 1 (2%) | 2 (4%) |
| Mineralization | 2 (4%) | 4 (8%) | 2 (4%) | |
| Thrombosis | 3 (6%) | 1 (2%) | 1 (2%) | |
| Myocardium, Vacuolization Cytoplasmic | | | 1 (2%) | |

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|-----------|----------|----------|----------|
| Adrenal Cortex | (50) | (50) | (50) | (50) |
| Angiectasis | | | 2 (4%) | 1 (2%) |
| Degeneration, Cystic | | | | 1 (2%) |
| Hematopoietic Cell Proliferation | 3 (6%) | 4 (8%) | 4 (8%) | 14 (28%) |
| Hyperplasia | | | 1 (2%) | |
| Hypertrophy | 4 (8%) | 2 (4%) | 5 (10%) | 2 (4%) |
| Subcapsular, Hyperplasia | 50 (100%) | 49 (98%) | 49 (98%) | 49 (98%) |
| Adrenal Medulla | (50) | (50) | (50) | (50) |
| Hyperplasia | 1 (2%) | 3 (6%) | 2 (4%) | 2 (4%) |
| Hypertrophy | | 1 (2%) | | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) |
| Hyperplasia | 35 (70%) | 15 (30%) | 12 (24%) | 8 (16%) |
| Parathyroid Gland | (45) | (47) | (39) | (38) |
| Cyst | | | 2 (5%) | 1 (3%) |
| Hyperplasia | | | 2 (5%) | |
| Pituitary Gland | (50) | (49) | (50) | (50) |
| Angiectasis | 1 (2%) | 1 (2%) | | |
| Hemorrhage | 1 (2%) | | 1 (2%) | 1 (2%) |
| Pars Distalis, Degeneration | | | | 1 (2%) |
| Pars Distalis, Hyperplasia | 17 (34%) | 18 (37%) | 19 (38%) | 17 (34%) |
| Thyroid Gland | (50) | (50) | (50) | (50) |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | | 2 (4%) | 2 (4%) |
| Follicular Cell, Hyperplasia | | 1 (2%) | | |

GENERAL BODY SYSTEM

| | | | | |
|--------------|----------|-----|-----|-----|
| Peritoneum | (1) | (0) | (0) | (0) |
| Inflammation | 1 (100%) | | | |
| Tissue NOS | (1) | (0) | (0) | (0) |

GENITAL SYSTEM

| | | | | |
|---|----------|----------|---------|---------|
| Clitoral Gland | (49) | (50) | (50) | (49) |
| Infiltration Cellular, Mononuclear Cell | | 2 (4%) | 2 (4%) | 1 (2%) |
| Inflammation | 10 (20%) | 10 (20%) | 8 (16%) | 9 (18%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Ovary | (50) | (50) | (50) | (50) |
| Angiectasis | | 1 (2%) | 2 (4%) | |
| Cyst | 7 (14%) | 15 (30%) | 13 (26%) | 14 (28%) |
| Infiltration Cellular, Mononuclear Cell | | 5 (10%) | 6 (12%) | |
| Inflammation | 2 (4%) | | 2 (4%) | 1 (2%) |
| Mineralization | 1 (2%) | | | 1 (2%) |
| Necrosis | 1 (2%) | | | |
| Pigmentation | 1 (2%) | | | |
| Thrombosis | | 1 (2%) | | |
| Germinal Epithelium, Hyperplasia | | 1 (2%) | 1 (2%) | 1 (2%) |
| Oviduct | (1) | (0) | (0) | (0) |
| Infiltration Cellular, Mononuclear Cell | 1 (100%) | | | |
| Uterus | (50) | (50) | (50) | (50) |
| Angiectasis | 1 (2%) | | 1 (2%) | |
| Inflammation | 7 (14%) | 6 (12%) | 8 (16%) | 4 (8%) |
| Pigmentation | | 1 (2%) | | |
| Thrombosis | 3 (6%) | | 1 (2%) | 1 (2%) |
| Ulcer | | 2 (4%) | 1 (2%) | |
| Cervix, Hyperplasia, Cystic | | | | 1 (2%) |
| Endometrium, Hyperplasia, Cystic | 46 (92%) | 46 (92%) | 46 (92%) | 43 (86%) |

HEMATOPOIETIC SYSTEM

| | | | | |
|---------------------------------------|----------|----------|----------|----------|
| Bone Marrow | (50) | (50) | (50) | (50) |
| Hyperplasia | 10 (20%) | 14 (28%) | 10 (20%) | 31 (62%) |
| Lymph Node | (19) | (13) | (18) | (29) |
| Axillary, Hyperplasia, Lymphoid | | | | 8 (28%) |
| Axillary, Inflammation | | | | 1 (3%) |
| Axillary, Pigmentation | | | | 1 (3%) |
| Bronchial, Hyperplasia, Lymphoid | 4 (21%) | 1 (8%) | 5 (28%) | 5 (17%) |
| Inguinal, Hyperplasia, Lymphoid | 4 (21%) | 2 (15%) | 7 (39%) | 17 (59%) |
| Inguinal, Inflammation, Granulomatous | 1 (5%) | | | |
| Lumbar, Angiectasis | | | 1 (6%) | |
| Lumbar, Hyperplasia, Lymphoid | 2 (11%) | | 1 (6%) | |
| Lumbar, Inflammation | 1 (5%) | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|--|----------|----------|----------|----------|
| Mediastinal, Hyperplasia, Lymphoid | | 2 (15%) | 1 (6%) | |
| Mediastinal, Infiltration Cellular, Histiocyte | 1 (5%) | | | |
| Pancreatic, Hyperplasia, Lymphoid | | | 2 (11%) | |
| Renal, Angiectasis | | | 1 (6%) | |
| Renal, Hyperplasia, Lymphoid | 1 (5%) | | | 1 (3%) |
| Lymph Node, Mandibular | (50) | (50) | (50) | (50) |
| Hyperplasia, Lymphoid | 14 (28%) | 19 (38%) | 23 (46%) | 27 (54%) |
| Inflammation | | | | 1 (2%) |
| Pigmentation | | | | 1 (2%) |
| Lymph Node, Mesenteric | (50) | (50) | (50) | (50) |
| Atrophy | | | 2 (4%) | |
| Hematopoietic Cell Proliferation | | | | 1 (2%) |
| Hyperplasia, Lymphoid | 13 (26%) | 12 (24%) | 13 (26%) | 4 (8%) |
| Inflammation | 2 (4%) | 1 (2%) | | 1 (2%) |
| Artery, Inflammation | | | | 1 (2%) |
| Spleen | (50) | (50) | (50) | (50) |
| Atrophy | | | 1 (2%) | |
| Hematopoietic Cell Proliferation | 35 (70%) | 35 (70%) | 30 (60%) | 34 (68%) |
| Hyperplasia, Lymphoid | 8 (16%) | 5 (10%) | 11 (22%) | 7 (14%) |
| Inflammation | 1 (2%) | | | |
| Pigmentation | 12 (24%) | 8 (16%) | 18 (36%) | 7 (14%) |
| Thymus | (50) | (50) | (48) | (49) |
| Angiectasis | | 1 (2%) | | |
| Atrophy | | 1 (2%) | 1 (2%) | |
| Hemorrhage | 1 (2%) | | | |
| Hyperplasia, Lymphoid | 18 (36%) | 21 (42%) | 25 (52%) | 22 (45%) |
| Inflammation | | | 1 (2%) | |

INTEGUMENTARY SYSTEM

| | | | | |
|------------------|---------|---------|--------|----------|
| Mammary Gland | (50) | (50) | (50) | (50) |
| Hyperplasia | 5 (10%) | 9 (18%) | 3 (6%) | 16 (32%) |
| Inflammation | | 2 (4%) | | 1 (2%) |
| Duct, Dilatation | | 1 (2%) | | 2 (4%) |
| Skin | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Abscess | | 1 (2%) | | |
| Fibrosis | 1 (2%) | 2 (4%) | 1 (2%) | 9 (18%) |
| Hyperkeratosis | 1 (2%) | 2 (4%) | 1 (2%) | 9 (18%) |
| Hyperplasia | 1 (2%) | 2 (4%) | 1 (2%) | 9 (18%) |
| Inflammation | 1 (2%) | | | 9 (18%) |
| Inflammation, Granulomatous | | 1 (2%) | | |
| Pigmentation | | | 1 (2%) | 1 (2%) |
| Ulcer | 1 (2%) | 1 (2%) | 1 (2%) | 9 (18%) |
| Control, Hyperplasia | | | | 2 (4%) |
| Control, Inflammation | 3 (6%) | | 1 (2%) | 2 (4%) |
| Sebaceous Gland, Hyperplasia | 1 (2%) | | 1 (2%) | 7 (14%) |
| Sebaceous Gland, Site Of Application, Hyperplasia | 1 (2%) | 2 (4%) | 6 (12%) | 34 (68%) |
| Site Of Application, Cyst | | | | 1 (2%) |
| Site Of Application, Fibrosis | 5 (10%) | 6 (12%) | 31 (62%) | 49 (98%) |
| Site Of Application, Hyperkeratosis | 24 (48%) | 38 (76%) | 49 (98%) | 49 (98%) |
| Site Of Application, Hyperplasia | 20 (40%) | 31 (62%) | 49 (98%) | 49 (98%) |
| Site Of Application, Infiltration Cellular, Mast Cell | | | 1 (2%) | 1 (2%) |
| Site Of Application, Inflammation | 12 (24%) | 14 (28%) | 42 (84%) | 48 (96%) |
| Site Of Application, Pigmentation | | | 35 (70%) | 40 (80%) |
| Site Of Application, Ulcer | 2 (4%) | | 3 (6%) | 33 (66%) |

MUSCULOSKELETAL SYSTEM

| | | | | |
|----------------------|---------|---------|---------|--------|
| Bone | (50) | (50) | (50) | (50) |
| Fibro-Osseous Lesion | 8 (16%) | 9 (18%) | 9 (18%) | 2 (4%) |
| Skeletal Muscle | (4) | (1) | (2) | (0) |
| Inflammation | 1 (25%) | | 1 (50%) | |

NERVOUS SYSTEM

| | | | | |
|---|--------|--------|--------|------|
| Brain | (50) | (50) | (50) | (50) |
| Developmental Malformation | | | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | 1 (2%) | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|--|----------|----------|----------|----------|
| Inflammation | 1 (2%) | | | 1 (2%) |
| Cerebrum, Vacuolization Cytoplasmic | | | 1 (2%) | |
| Peripheral Nerve | (2) | (0) | (0) | (0) |
| Sciatic, Atrophy | 1 (50%) | | | |
| Sciatic, Infiltration Cellular, Mononuclear Cell | 1 (50%) | | | |
| Spinal Cord | (2) | (0) | (0) | (0) |
| Atrophy | 1 (50%) | | | |
| Degeneration | 1 (50%) | | | |
| RESPIRATORY SYSTEM | | | | |
| Lung | (50) | (50) | (50) | (50) |
| Fibrosis | | | | 1 (2%) |
| Infiltration Cellular, Histiocyte | 2 (4%) | 6 (12%) | 2 (4%) | 2 (4%) |
| Inflammation | 3 (6%) | 5 (10%) | 1 (2%) | 2 (4%) |
| Metaplasia, Osseous | 2 (4%) | | | |
| Pigmentation | 1 (2%) | | 1 (2%) | |
| Thrombosis | 1 (2%) | | | |
| Artery, Mineralization | 1 (2%) | | | |
| Bronchiole, Hyperplasia | | 1 (2%) | | 1 (2%) |
| Nose | (50) | (50) | (50) | (50) |
| Inflammation | 13 (26%) | 9 (18%) | 17 (34%) | 9 (18%) |
| Polyp, Inflammatory | | | 1 (2%) | |
| Glands, Dilatation | 2 (4%) | | | |
| Glands, Metaplasia | 6 (12%) | 7 (14%) | 3 (6%) | 7 (14%) |
| Olfactory Epithelium, Hyperplasia | | | 1 (2%) | |
| Olfactory Epithelium, Metaplasia | | 3 (6%) | 2 (4%) | 2 (4%) |
| Respiratory Epithelium, Foreign Body | | | 1 (2%) | |
| Respiratory Epithelium, Hemorrhage | 1 (2%) | | 1 (2%) | |
| Respiratory Epithelium, Hyperplasia | 46 (92%) | 48 (96%) | 46 (92%) | 46 (92%) |
| Turbinate, Thrombosis | 1 (2%) | | | |
| Trachea | (50) | (50) | (50) | (50) |
| Inflammation | | | 1 (2%) | |
| Epithelium, Hyperplasia | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| SPECIAL SENSES SYSTEM | | | | |
| Eye | (50) | (50) | (50) | (50) |
| Atrophy | | | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | 1 (2%) | 1 (2%) | | 1 (2%) |
| Inflammation | 2 (4%) | | 1 (2%) | 3 (6%) |
| Cornea, Hyperplasia | 1 (2%) | | | |
| Retina, Angiectasis | | | 1 (2%) | |
| Retina, Degeneration | | 1 (2%) | | |
| Harderian Gland | (50) | (50) | (50) | (50) |
| Atrophy | | | 1 (2%) | |
| Cyst | 1 (2%) | | | |
| Hyperplasia | 3 (6%) | 9 (18%) | 6 (12%) | 5 (10%) |
| Infiltration Cellular, Mononuclear Cell | 29 (58%) | 33 (66%) | 31 (62%) | 24 (48%) |
| Inflammation | 1 (2%) | | | |
| Mineralization | | | | 1 (2%) |
| Lacrimal Gland | (0) | (0) | (1) | (0) |

URINARY SYSTEM

| | | | | |
|---|----------|----------|----------|----------|
| Kidney | (50) | (50) | (50) | (50) |
| Accumulation, Hyaline Droplet | 2 (4%) | 3 (6%) | 2 (4%) | |
| Cyst | | | 1 (2%) | |
| Dilatation | | 1 (2%) | | 2 (4%) |
| Infarct, Chronic | | | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | 2 (4%) | 5 (10%) | 4 (8%) | 4 (8%) |
| Inflammation | 1 (2%) | | | 3 (6%) |
| Metaplasia, Osseous | 3 (6%) | 1 (2%) | 1 (2%) | 2 (4%) |
| Mineralization | 12 (24%) | 7 (14%) | 8 (16%) | 7 (14%) |
| Nephropathy | 33 (66%) | 24 (48%) | 28 (56%) | 28 (56%) |
| Pigmentation | 3 (6%) | 1 (2%) | 1 (2%) | |
| Papilla, Necrosis | | | | 1 (2%) |
| Renal Tubule, Degeneration | 1 (2%) | 1 (2%) | 1 (2%) | |
| Renal Tubule, Hyperplasia | 1 (2%) | | | |
| Renal Tubule, Vacuolization Cytoplasmic | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
Pyrogallol
CAS Number: 87-66-1

Date Report Requested: 08/17/2010
Time Report Requested: 13:34:47
First Dose M/F: 09/21/04 / 09/20/04
Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 5 MG/KG | 20 MG/KG | 75 MG/KG |
|---|----------|----------|----------|----------|
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Infiltration Cellular, Mononuclear Cell | 34 (68%) | 37 (74%) | 37 (74%) | 42 (84%) |
| Inflammation | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) |

*** END OF REPORT ***